A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study

PHASE2TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 27, 2018

Primary Completion Date

October 23, 2019

Study Completion Date

October 23, 2019

Conditions
Urticaria
Interventions
DRUG

GDC-0853

Participants were administered GDC-0853 200mg orally, as per the dosing schedules described above.

Trial Locations (10)

34470

Renstar Medical Research, Ocala

35209

Clinical Research Center of Alabama, LLC, Birmingham

74136

Vital Prospects Clinical Research Institute PC - CRN, Tulsa

85251

Allergy & Asthma Immunology Associates, Scottsdale

92506

Integrated Research Group Inc, Riverside

92691

Southern California Research Center, Mission Viejo

93301

Kern Allergy Med Clinic, Inc., Bakersfield

94063

Allergy & Asthma Consultants, Redwood City

02914

Asthma, Nasal Disease, and Allergy Research Center of New England, East Providence

05403

Timber Lane Allergy and Asthma Research, LLC, Burlington

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY